If you’ve been paying attention to the autoimmune space, you’ve noticed a theme: everyone wants to modulate inflammation, but very few are going after the structural damage that inflammation leaves behind. Neutrolis is doing something genuinely different — they’re targeting the wreckage itself. And today they announced positive Phase 1a data from the LIBERATE-I trial of NTR-1011, a first-in-class DNASE1L3 fusion protein designed to dismantle neutrophil extracellular traps — NETs.

Quick biology refresher: NETs are web-like structures that neutrophils spit out to trap pathogens. Useful when you have an infection. Catastrophic when your immune system is misfiring. In diseases like lupus and rheumatoid arthritis, NETs accumulate, drive tissue damage, and perpetuate the inflammatory cycle. They’re not a side effect of autoimmunity — they’re an accelerant. And until now, nobody had a clinical-stage drug designed to clear them.

The Phase 1a results in healthy volunteers showed a favorable safety, tolerability, and immunogenicity profile across multiple IV and SC dose levels. Predictable pharmacokinetics. Strong subcutaneous bioavailability — which matters because this is designed as a chronic therapy, and nobody wants to sit in an infusion chair every two weeks if they don’t have to. Phase 1b in actual SLE and RA patients is planned for mid-2026.

Here’s the part that gets really interesting: NETs aren’t just an autoimmune story. There’s a growing body of evidence linking NETs to tumor progression, metastasis, and cancer immunotherapy resistance. NET formation in the tumor microenvironment has been shown to shield cancer cells from immune attack and promote angiogenesis. If NTR-1011 can safely clear NETs in autoimmune patients, the oncology implications are… significant. Neutrolis hasn’t announced cancer indications yet, but the biology is screaming for it.

Cambridge, MA-based Neutrolis is still early — Phase 1 early — but first-in-class mechanisms with clean safety data and a platform biology that spans autoimmunity and oncology? That’s exactly the kind of story that draws a second look from pharma BD teams. Watch this one.